Diabetes type 1 and type 2 are one of the most common chronic diseases prevalent in the world, affecting millions of people. One of the disorders associated with diabetes type 1 and type 2 is gastroparesis, which is characterized by the delayed emptying of the stomach. One of the major causes of gastroparesis is damage to the vagus nerve, reducing the mobility of the stomach contents. Diabetic neuropathy affects the vagus nerve, in cases where the blood glucose levels remain high over a longer duration. Diabetes gastroparesis is usually diagnosed with the help of imaging techniques such as ultrasound and x-ray, which is accompanied by the intake of radio isotopic meals containing barium, or using hematological / blood tests, and endoscopic techniques. There has been a marked increase in the prevalence of diabetes, especially in the developing countries, including China, India, Brazil, and some other Asian countries, leading to increasing incidence of diabetic neuropathy and consequent rise in diabetes gastroparesis around the world.
Obtain Report Details @
The global diabetes gastroparesis market is segmented on the basis of drug class, disease indications, and distribution channels. The drug class segment of the global diabetes gastroparesis market is further segmented into antihistamines, antibiotics, anti-emetics, and others. The disease indication segment is segmented into compensated gastroparesis and gastric failure. The distribution channels segment is further segmented into hospital pharmacies, online pharmacies, retail pharmacies, and drug stores. Among the distribution channels segment, the hospital pharmacies segment is expected to dominate the global diabetes gastroparesis market during 2017-2025.
Rising prevalence of diabetes, increasing geriatric population, and sedentary lifestyle habits are some of the major factors responsible for the growth of the diabetes gastroparesis market in recent years. According to the International Diabetes Federation (IDF), and World Health Organization (WHO) statistics, in 2014, an estimated 422 million people in the world were suffering from diabetes. Also, the global prevalence rate of diabetes in adults has increased from 4.7% (of total population) in 1980, to 8.5% (of total population) in 2014. The World Health Organization (WHO) estimates that diabetes will be the 7th leading cause of death in the world by 2030. Increasing geriatric population around the world and sedentary lifestyles have led to increasing incidence of diabetic cases at an alarming rate. These are some of the major factors likely to be responsible for driving the growth of the global diabetes gastroparesis market during 2017-2025.
Region wise, the global diabetes gastroparesis market is segmented into five major regions – North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is expected to dominate the global diabetes gastroparesis market in 2016, owing to large patient population suffering from diabetes, and changing lifestyle habits. According to International Diabetes Federation (IDF), out of the estimated 422 million people in the world suffering from diabetes, an estimated 230 million people were living in the Asia Pacific region. Also, the geriatric population in countries of Asia Pacific region such as China, India, and Japan, are among the highest in the world, and increasing life expectancy in these countries is contributing to rise in prevalence of diabetes and diabetic neuropathy, leading to increasing incidence of diabetes gastroparesis. North America accounted for the second largest market share of the global diabetes gastroparesis market followed by Europe. However, the Middle East & Africa region is expected to register the highest CAGR in the global diabetes gastroparesis market during 2017-2025, owing to maximum incidence rate of diabetes in countries including Saudi Arabia, UAE, and Qatar.
Some of the key players in the global diabetes gastroparesis market are Medtronic, Kimberly-Clark Corporation, Abbott Laboratories, Salix Pharmaceuticals, Inc., Boston Scientific Corporation, C. R. Bard, Inc., Janssen Global Services, LLC, Cardinal Health, Inc., Alfa Wassermann SPA, Evoke Pharma, and Rhythm Pharmaceuticals, Inc., among others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Fill the form for an exclusive sample of this report @
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453
Browse market research blog:
Tagged: Diabetes Gastroparesis Market